Biology Reference
In-Depth Information
REFERENCES
Autran B, Carcelain G, Li TS, Gorochov G, Blanc C, Renaud M, Durali M, Mathez D, Calvez V,
Leibowitch J, Debre P. 1999. Restoration of the immune system with anti-retroviral therapy.
Immunol Lett 66: 207±211.
Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hammer SM, Hirsch MS, Ja-
cobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schechter M, Schooley
RT, Thompson MA, Vella S, Yeni PG, Volberding PA. 2000. Antiretroviral therapy in adults.
Updated recommendations of the International AIDS Society-USA panel. JAMA 283: 381±390.
Carr A, Cooper DA. 2000. Adverse e¨ects of antiretroviral therapy. Lancet 356: 1423±1430.
Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. 1999. Diagnosis,
prediction and natural course of HIV-1 protease inhibitor-associated lipodystrophy, hyper-
lipidemia and diabetes mellitus. Lancet 351: 1328.
Chaisson RE, Keruly JC, Moore RD. 2000. Association of initial CD4 cell count and viral load
with response to highly active antiretroviral therapy. JAMA 284: 3128±3129.
Chun TW, Engel D, Mizell SB, Hallahan CW, Fischette M, Park S, Davey Jr RT, Dybul M,
Kovacs JA, Metcalf JA, Mican JM, Berrey MM, Corey L, Lane HC, Fauci AS. 1999. E¨ect of
interleukin-2 on the pool of latently infected, resting CD4
T cells in HIV-1-infected patients
receiving highly active anti-retroviral therapy. Nat Med 6: 651±655.
Davey RT, Murphy RL, Graziano FM, Boswell SL, Pavia AT, Cancio M, Nadler JP, Chaitt DG,
Dewar RL, Sahner DK, Duliege AM, Capra WB, Leong WP, Giedlin MA, Lane HC, Kahn
JO. 2000. Immunologic and virologic e¨ects of subcutaneous interleukin 2 in combination with
antiretroviral therapy: a randomized controlled trial. JAMA 284: 183±189.
Deeks SG, Wrin T, Liegler T, Hoh R, Hayden M, Barbour JD, Hellmann NS, Petropoulos CJ,
McCune JM, Hellerstein MK, Grant RM. 2001. Virologic and immunologic consequences of
discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable
viremia. N Engl J Med 344: 472±480.
Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, Smith K, Lisziewicz J,
Lori, F, Flexner C, Quinn TC, Chaisson RE, Rosenberg E, Walker B, Gange S, Gallant J,
Siliciano RF. 1999. Latent infection of CD4
T cells provides a mechanism for lifelong persis-
tence of HIV-1, even in patients on e¨ective combination therapy. Nat Med 5: 512±517.
Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, Eron JJ, Feinberg
JE, Balfour HH, Deyton LR, Chodakewitz JA, Fischl MA. 1997. A controlled trial of two
nucleoside analogues plus indinavir in persons with human immunode®ciency virus infection
and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 337: 725±733.
Haslett PA, Nixon DF, Shen Z, Larsson M, Cox WI, Manandhar R, Donahoe SM, Kaplan G.
2000. Strong human immunode®ciency virus (HIV)-speci®c CD4
T cell responses in a cohort
of chronically infected patients are associated with interruptions in anti-HIV chemotherapy. J
Infect Dis 181: 1264±1272.
Haubrich RH, Little SJ, Currier JS, Forthal DN, Kemper CA, Beall GN, Johnson D, Dube MP,
Hwang JY, McCutchan JA. 1999. The value of patient-reported adherence to antiretroviral
therapy in predicting virologic and immunologic response. AIDS 13: 1099±1107.
Hirsch MS, Brun-Vezinet F, D'Aquila RT, et al. 2000. Antiretrroviral drug resistance testing in
adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA
283: 2417±2426.
Kaufmann GR, Bloch M, Zaunders JJ, Smith D, Cooper DA. 2000. Long-term immunological re-
sponse in HIV-1-infected subjects receiving potent antiretroviral therapy. AIDS 14: 959±969.
Lori F, Lewis MG, Xu J, Varga G, Zinn DE, Crabbs C, Wagner W, Greenhouse J, Silvera P,
Yalley Ogunro J, Tinelli C, Lisziewicz J. 2000. Control of SIV rebound through structured
treatment interruptions during early infection. Science 290: 1591±1593.
